These results suggest that prophylaxis with rFVIIIFc in patients with hemophilia A may allow less frequent prophylactic dosing while maintaining efficacy, with comparable prophylactic consumption” Schafer et al (2017).
Abstract:
Prophylaxis for hemophilia A with conventional factor VIII (FVIII) products requires frequent intravenous dosing, which may reduce adherence. Recombinant factor VIII Fc fusion protein (rFVIIIFc) has a prolonged half-life compared with conventional rFVIII, and has demonstrated safety and efficacy for the prevention and treatment of bleeding episodes in phase 3 studies of patients with severe hemophilia A.
[ctt link=”6NdPK” template=”1″]ReTweet if useful… Pharmacokinetics of Recombinant Factor VIII Fc fusion protein https://ctt.ec/6NdPK+ @ivteam #ivteam[/ctt]
Most subjects experienced reduced prophylactic dosing frequency with rFVIIIFc compared with prestudy FVIII; the median total weekly prophylactic consumption was comparable. No subjects developed inhibitors. These results suggest that prophylaxis with rFVIIIFc in patients with hemophilia A may allow less frequent prophylactic dosing while maintaining efficacy, with comparable prophylactic consumption.
Reference:
Schafer, K., Munn, J., Khair, K., Thukral, N., Tom, A. and McAlister, S. (2017) Pharmacokinetics, Safety, and Efficacy of Recombinant Factor VIII Fc Fusion Protein: A Practical Review. Journal of Infusion Nursing. 40(1), p.65-75.
doi: 10.1097/NAN.0000000000000205.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]